Profile
Elie K.
Farah worked as President, Chief Executive Officer & Director at Merus Labs International, Inc. from 2013 to 2014.
He was also a Director at Inventus Mining Corp.
in 2012.
Prior to that, he was the President, CFO & Head-Investor Relations at Transition Therapeutics, Inc. from 2010 to 2011.
He also worked as the Chief Financial Officer at NeuroMedix, Inc. and as a Principal at Boehringer Ingelheim GmbH and Pricewaterhouse & Co.
Former positions of Elie K. Farah
| Companies | Position | End |
|---|---|---|
| MERUS LABS INTERNATIONAL INC | Chief Executive Officer | 2014-09-22 |
| TRANSITION THERAPEUTICS INC | Director of Finance/CFO | 2011-02-08 |
| INVENTUS MINING CORP. | Director/Board Member | - |
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | - |
| Pricewaterhouse & Co. | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| INVENTUS MINING CORP. | Non-Energy Minerals |
| Private companies | 5 |
|---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Transition Therapeutics, Inc.
 Transition Therapeutics, Inc. Medical SpecialtiesHealth Technology Transition Therapeutics, Inc. develops novel therapeutics for disease indications. It operates through research and development of therapeutic agents segment. The firm's products include ELND005 for the treatment of alzheimer's disease, bipolar disorder and down syndrome. Its metabolic drug candidate is TT401 for treatment of type 2 diabetes and accompanying obesity. Transition Therapeutics was founded by Tony F. Cruz on July 6, 1998 and is headquartered in Toronto, Canada. | Health Technology |
NeuroMedix, Inc.
 NeuroMedix, Inc. Pharmaceuticals: MajorHealth Technology NeuroMedix, Inc. develops pharmaceutical products. The company makes therapeutic agents for the treatment of degenerative and inflammatory diseases of the central nervous system, such as Alzheimer's disease and multiple sclerosis. It also develops therapies for the treatment of other degenerative neuroinflammatory diseases, such as Parkinson's. NeuroMedix was founded in 2005 and is headquartered in Toronto, Canada. | Health Technology |
| Pricewaterhouse & Co. | Commercial Services |
Merus Labs International, Inc.
 Merus Labs International, Inc. Pharmaceuticals: MajorHealth Technology Merus Labs International, Inc. wass a pharmaceutical company. It was engaged in the acquisition of mature prescription and over the counter pharmaceutical products and licensing in of novel hospital products. The company was founded by Ahmad Doroudian on December 19, 2011 and it was headquartered in Vancouver, Canada. | Health Technology |
- Stock Market
- Insiders
- Elie K. Farah
